Pharmacotherapy for the prevention of post-ERCP pancreatitis

American Journal of Gastroenterology

Volumn 102, Issue 1, 2007, Pages 52-55

  Foster, Erina ^a   Leung, Joseph ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BOTULINUM TOXIN; GABEXATE; GABEXATE MESILATE; GASTROINTESTINAL AGENT; INTERLEUKIN 10; LIDOCAINE; LOW MOLECULAR WEIGHT HEPARIN; NIFEDIPINE; OCTREOTIDE; PREDNISONE; SOMATOSTATIN; ULINASTATIN;

AEROSOL; CLINICAL TRIAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; HIGH RISK PATIENT; HUMAN; MUSCLE CONTRACTILITY; PANCREAS DUCT; PANCREAS SECRETION; PANCREAS STENTING; PANCREATITIS; PRESSURE; PRIORITY JOURNAL; REVIEW; SPHINCTER; STENT;

CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; GASTROINTESTINAL AGENTS; HUMANS; OCTREOTIDE; PANCREATITIS; RANDOMIZED CONTROLLED TRIALS;

EID: 33846063359     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2006.00950.x     Document Type: Review

References (35)

1. Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy. Complications of ERCP. Gastrointest Endosc 2003;57:633-8.
2. Tarnasky PR. Mechanical prevention of post-ERCP pancreatitis by pancreatic stents: Results, techniques, and indications. JOP 2003;4:58-67.
3. Freeman ML. Understanding risk factors and avoiding complications with endoscopic retrograde cholangiopancreatography. Curr Gastroenterol Rep 2003;5:145-53.
4. Freeman ML, DiSario JA, Nelson DB, et al. Risk factors for post-ERCP pancreatitis: A prospective, multicenter study. Gastrointest Endosc 2001;54:425-34.
5. Freeman ML, Guda NM. Prevention of post-ERCP pancreatitis: A comprehensive review. Gastrointes Endosc 2004;59:845-64.
6. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-18.
7. Schwartz JJ, Lew RJ, Ahmad NA, et al. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc 2004;59:179-84.
8. Prat F, Amaris J, Ducot B, et al. Nifedipine for prevention of post-ERCP pancreatitis: A prospective, double-blind randoized study. Gastrointest Endosc 2002;56:202-8.
9. Rabenstein T, Fishcer B, Wiessner V, et al. Low-molecular-weight heparin does not prevent acute post-ERCP pancreatitis. Gastrointest Endosc 2004;59:606-13.
10. Dumot JA, Conwell DL, O'Connor JB, et al. Pretreatment with methylprednisolone to prevent ERCP-induced pancreatitis: A randomized, multicenter, placebo-controlled clinical trial. Am J Gastroenterol 1998;93:61-5.
11. Cheng C, Sherman S, Watkins JL, et al. Risk factors for Post-ERCP pancreatitis: A prospective multicenter study. Am J Gastroenterol 2006:101:139-47.
12. Dumot JA, Conwell DL, Zuccaro G Jr, et al. A randomized, double blind study of interleukin 10 for the prevention of ERCP-induced pancreatitis. Am J Gastroenterol 2001;96:2098-102.
13. Deviere J, Le Moine O, Van Laethem JL, et al. Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography. Gastroenterology 2001;120:498-505.
14. Gorelick A, Bamett J, Chey W, et al. Botulinom toxin injection after biliary sphincterotomy. Endoscopy 2004;36:170-3.
15. Poon RT-P, Yeung C, Lo C-M, et al. Prophylactic effect of somatostatin on post-ERCP pancreatitis: A randomized controlled trial. Gastrointest Endosc 1999;49:593-8.
16. Poon RT-P, Yeung C, Liu C-L, et al. Intravenous bolus somatostatin after diagnostic cholangiopancreatography reduces the incidence of pancreatitis associated with therapeutic endoscopic retrograde cholangiopancreatography procedures: A randomised controlled trial. Gut 2003;52:1768-73.
17. Arvanitidis D, Anagnostopoulos GK, Giannopoulos D, et al. Can somatostatin prevent post-ERCP pancreatitis? Results of a randomized controlled trial. J Gastroenterol Hepatol 2004;19:278-82.
18. Andriulli A, Clemente R, Solmi L, et al. Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: A multicenter, placebo-controlled, randomized clinical trial. Gastrointest Endosc 2002;56:488-95.
19. Andriulli A, Solmi L, Loperfido S, et al. Prophylaxis of ERCP-related pancreatitis: A randomized, controlled trial of somatostatin and gabexate mesylate. Clin Gastroenterol Hepatol 2004;2:713-8.
20. Moreto M, Zaballa M, Casado I, et al. Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial. Gastrointest Endosc 2003;57:1-7.
21. Sudhindran S, Bromwich E, Edwards PR. Prospective randomized double-blind placebo controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography-induced pancreatitis. Br J Surg 2001;88:1178-82.
22. Kaffes AJ, Bourke MJ, Ding S, et al. A prospective, randomized, placebo-controlled trial of transdermal glyceryl trinitrate in ERCP: Effects on technical success and posto-ERCP pancreatitis. Gastrointes Endosc 2006;64:351-7.
23. Hoogerwerf WA. Pharmacological management of pancreatitis. Curr Opin Pharmacol 2005;5:578-82.
24. Fujishiro H, Adachi K, Imaoka T, et al. Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study. J Gastroenterol Hepatol 2006;21:1065-9.
25. Sternlieb JM, Aronchick CA, Retig JN, et al. A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis. Am J Gastroenterol 1992;87:1561-6.
26. Binmoeller KF, Dumas R, Harris AG, et al. Effect of somatostatin analog octreotide on human sphincter of Oddi. Dig Dis Sci 1992;37:773-7.
27. Andriulli A, Leandro G, Niro G, et al. Pharmacologic treatment can prevent pancreatic injury after ERCP: A metaanalysis. Gastrointes Endosc 2000;51:1-7.
28. Binmoeller KF, Harris AG, Dumas R, et al. Does the somatostatin analogue octreotide protect against ERCP induced pancreatitis? Gut 1992;33:1129-33.
29. Tulassay Z, Döbrönte Z, Prónai L, et al. Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography. Aliment Pharmacol Ther 1998;12:1109-12.
30. Hardt PD, Kress O, Fadgyas T, et al. Octreotide in the prevention of pancreatic damage induced by endoscopic sphincterotomy. Eur J Med Res 2000;5:165-70.
31. Testoni PA, Bagnolo F, Andriulli A, et al. Octreotide 24-h prophylaxis in patients at high risk for post-ERCP pancreatitis: Results of a multicenter, randomized, controlled trial. Aliment Pharmacol Ther 2001;15:965-72.
32. Li Z-S, Pan X, Zhang W-J, et al. Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial. Am J Gastroenterol 2006;101:46-51.
33. Tarnasky PR, Palesch YY, Cunningham JT, et al. Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology 1998;115:1518-24.
34. Fazel A, Quadri A, Catalano MF, et al. Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc 2003;57:291-4.
35. Leung JW, Vallero R, Chin A. Prevention of post-ERCP pancreatitis by patient positioning. Gastrointest Endosc 2002;55AB:150-7.